Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

Age: 10 years to 65 years old

Healthy Volunteers:

This study is NOT accepting healthy volunteers

Key

Inclusion Criteria:

Part A: * APOL1 genotype of G1/G1, G2/G2, or G1/G2 * Proteinuric kidney disease Part B: \- Completion of Treatment Period in Part A and no permanent discontinuation of study drug. Key

Exclusion Criteria:

Part A: * Solid organ or bone marrow transplant * Uncontrolled hypertension * History of diabetes mellitus * Known underlying cause of kidney disease including but not limited to sickle cell disease Part B: * ESKD (End Stage Kidney Disease) as defined in the protocol. * Any lab abnormality that may pose a safety risk to the participant, as judged by the investigator. Other protocol defined Inclusion/Exclusion criteria will apply.

Interventions:

DRUG: VX-147, DRUG: Placebo

Conditions:

Proteinuric Kidney Disease

Keywords:

APOL1-mediated kidney disease (AMKD)

Contact(s): Medical Information - medicalinfo@vrtx.com

Principal Investigator:

IRB Number:

System ID: NCT05312879

Thank you for choosing StudyFinder. Please visit http://studyfinder.cctr.vcu.edu to find a Study which is right for you and contact ctrrecruit@vcu.edu if you have questions or need assistance.

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

Email this study information to me

Contact the study team